AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to ...

Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.

Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the final patient has ...

Repare Therapeutics ( ($RPTX) ) has issued an update. On December 23, 2025, Repare Therapeutics entered into an asset purchase agreement under ...

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the final patient has ...

Detailed price information for Repare Therapeutics Inc (RPTX-Q) from The Globe and Mail including charting and trades.

Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.

CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement ...

Medera has completed patient dosing in Cohort B of its ongoing MUSIC-HFpEF Phase I/IIa study of SRD-002 for heart failure ...

Gilead Sciences announced a cancer drug acquisition from Repare Therapeutics for up to $30M. This deal expands Gilead's ...